Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare, primary humoral immunodeficiency of childhood characterized by decreasing serum levels of immunoglobulin G (IgG) as maternal antibodies clear the circulation while serum levels of immunoglobulin A and immunoglobulin M remain normal or are slightly decreased. Diagnosis may be suspected after the age of six months when a child's own synthesis of IgG should accelerate but it must be confirmed retrospectively after normalization of all serum immunoglobulin levels is seen by ages 2-6. This disorder may be caused by inadequate activation of progenitor B cells, defective class-switching or may even represent a maturational variant. Typically, a normal response to protein antigens is found while there is a notably diminished response to viral and bacterial polysaccharide antigens. Clinical presentation may include recurrent infections especially those of the respiratory tract. Despite increased susceptibility to infection in childhood, this disorder is self-limited with minimal implications for a normal life span.
Biomarker and diagnostic research for transient hypogammaglobulinemia of infancy has been reported in the published literature.
No clinical trials have been registered for transient hypogammaglobulinemia of infancy.
10 publications have been identified in PubMed for transient hypogammaglobulinemia of infancy. Research spans Review / Meta-Analysis (40%), Epidemiology / Natural History (30%), and Diagnostic / Biomarker (10%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 4 | 40% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:40 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Disease patterns and progression
3 |
30% |
Testing and diagnosis research | 1 | 10% |
Patient case studies | 1 | 10% |
Clinical study results | 1 | 10% |
Justiz Vaillant AA (2026). [PMID: 31335076](https://pubmed.ncbi.nlm.nih.gov/31335076/). *Unknown Journal*. [Review / Meta-Analysis]
Kose H (2026). [PMID: 41705238](https://pubmed.ncbi.nlm.nih.gov/41705238/). *Front Immunol*. [Case Report / Case Series]
Ozkan E (2026). [PMID: 41712476](https://pubmed.ncbi.nlm.nih.gov/41712476/). *Int Arch Allergy Immunol*. [Epidemiology / Natural History]
Öztürk G (2026). [PMID: 42096373](https://pubmed.ncbi.nlm.nih.gov/42096373/). *Int Arch Allergy Immunol*. [Diagnostic / Biomarker]
Celiksoy MH (2025). [PMID: 40380357](https://pubmed.ncbi.nlm.nih.gov/40380357/). *Allergy Asthma Proc*. [Epidemiology / Natural History]
Ameratunga R (2025). [PMID: 41324804](https://pubmed.ncbi.nlm.nih.gov/41324804/). *Clin Rev Allergy Immunol*. [Review / Meta-Analysis]
Demirtaş Güner D (2025). [PMID: 40270942](https://pubmed.ncbi.nlm.nih.gov/40270942/). *Front Pediatr*. [Epidemiology / Natural History]
Sgrulletti M (2024). [PMID: 39124588](https://pubmed.ncbi.nlm.nih.gov/39124588/). *J Clin Med*. [Clinical Trial Publication]
Szaflarska A (2024). [PMID: 38306460](https://pubmed.ncbi.nlm.nih.gov/38306460/). *Clin Exp Immunol*. [Review / Meta-Analysis]
Darmawan D (2024). [PMID: 37667006](https://pubmed.ncbi.nlm.nih.gov/37667006/). *J Perinatol*. [Review / Meta-Analysis]